Kazia Therapeutics (KZIA) Common Equity (2017 - 2025)

Kazia Therapeutics (KZIA) has disclosed Common Equity for 4 consecutive years, with -$5.3 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Common Equity rose 19.47% year-over-year to -$5.3 million, compared with a TTM value of -$5.3 million through Jun 2025, up 19.47%, and an annual FY2025 reading of -$5.4 million, up 18.11% over the prior year.
  • Common Equity was -$5.3 million for Q2 2025 at Kazia Therapeutics, up from -$6.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $13.1 million in Q2 2022 and bottomed at -$6.6 million in Q2 2024.
  • Average Common Equity over 4 years is $2.3 million, with a median of $1.4 million recorded in 2023.
  • The sharpest move saw Common Equity plummeted 181.97% in 2024, then increased 19.47% in 2025.
  • Year by year, Common Equity stood at $13.1 million in 2022, then tumbled by 38.47% to $8.1 million in 2023, then tumbled by 181.97% to -$6.6 million in 2024, then rose by 19.47% to -$5.3 million in 2025.
  • Business Quant data shows Common Equity for KZIA at -$5.3 million in Q2 2025, -$6.6 million in Q2 2024, and $8.1 million in Q2 2023.